ALB and ovarian cancer: For example, a recombinant fusion of IL-12 with an albumin-binding domain utilizes human serum albumin transport pathways to improve tumor accumulation and is now in a Phase I/II trial (NCT05756907) for patients with advanced solid tumors and platinum-resistant ovarian cancer (193).